SNA vs INCY Comparison

Snap-on is a manufacturer of premium tools, equipment, and diagnostics for professional technicians, primarily involved in the repair of passenger cars, but has expanded into other industrial applications. The company's legacy business is selling hand tools through franchisee-operated mobile vans to technicians who purchase the tools at their own expense. The company also operates a commercial and industrial business, focusing on repair facilities that serve other industries. The third segment, repair systems and information, targets auto OEMs and large dealerships more directly, also offering substantial diagnostic solutions to aid in repairs. The company's finance arm provides financing to franchisees to support their operations, as well as underwrites end-customer purchases.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.